(S)-3-Aminobutanenitrile hydrochloride

(S)-3-Aminobutanenitrile hydrochloride (CAS 1073666-54-2), also known as (3S)-3-aminobutanenitrile hydrochloride or (S)-3-aminobutyronitrile hydrochloride, is a chiral β-aminonitrile compound with the molecular formula C₄H₉ClN₂ and a molecular weight of 120.58 g/mol. It typically appears as a white to off-white crystalline powder with good solubility in various organic solvents such as ethanol and acetone.  The hydrochloride salt form ensures enhanced stability, water solubility, and improved handling characteristics compared to the free base, making it a reliable reagent for sensitive synthetic transformations.

(S)-3-Aminobutanenitrile hydrochloride is a high-value chiral amino nitrile compound. Possessing a chiral center with a specific (S)-configuration, (S)-3-aminobutanenitrile hydrochloride serves as a critical chiral building block in medicinal chemistry, pesticide chemistry, and asymmetric synthesis.  The presence of both amino and nitrile functional groups in its molecular structure imparts rich chemical reactivity, enabling the construction of more complex chiral molecular frameworks, particularly those containing β-amino structural motifs.

In pharmaceutical research, (S)-3-aminobutanenitrile hydrochloride has gained significant attention as a key intermediate in the synthesis of non-peptide HIV protease inhibitors, which play a critical role in antiretroviral therapy by obstructing the activity of the HIV protease enzyme, an essential component for viral replication. Beyond its application in HIV therapeutics, (S)-3-aminobutanenitrile hydrochloride is extensively utilized as a chiral pharmaceutical intermediate and building block for asymmetric synthesis, particularly in the preparation of β-amino alcohol compounds and other chiral drugs.  It has also been identified as a documented chiral intermediate for the synthesis of Orforglipron (a GLP‑1 agonist), with its (S)-enantiomer being a key active structural unit of drug molecules.  Additionally, (S)-3-aminobutanenitrile hydrochloride is a raw material for preparing high‑efficiency, low‑toxicity chiral pesticides, such as fungicides and insecticides, and can be used as a chiral building block to synthesize various fine chemicals, including chiral ligands and optically active materials.

Product Parameters

Synthetic Routes

The synthesis of (S)-3-aminobutanenitrile hydrochloride has been achieved through various enantioselective approaches:

Method 1: Reaction with Hydrochloric Acid

The compound can be synthesized by the direct reaction of (S)-3-aminobutanenitrile with hydrochloric acid in an aqueous medium, followed by isolation of the hydrochloride salt through crystallization. The reaction is typically carried out under controlled conditions to ensure purity and yield, with the resulting salt being isolated by crystallization from an appropriate solvent.

Method 2: Asymmetric Hydrogenation (Scalable Route)

Another synthetic route involves asymmetric hydrogenation of suitable precursors using chiral catalysts. Advances in catalysis, particularly with chiral ligands, have enabled efficient and scalable production of the (S)-enantiomer with high optical purity.

Method 3: High‑Purity Industrial Synthesis (Cyanide‑Free, Documented)

An industrial‑scale synthetic protocol has been developed and validated at the pilot‑plant level. This approach offers high chemical and optical yields while employing a cyanide‑free synthetic design, significantly reducing environmental impact and operational safety risks. The process is conducted without the use of highly toxic cyanide reagents, making it suitable for environmentally responsible manufacturing. The product exhibits excellent stereochemical control and consistent purity across production batches. This method has been successfully scaled to multi‑kilogram quantities with reproducible quality. [13†L6-L7]

Industrial Production Methods

Industrial production of (S)-3-aminobutanenitrile hydrochloride can be scaled up using continuous flow reactors and automated systems to enhance efficiency, yield, and safety. The process involves careful handling of reagents and optimization of reaction parameters to achieve high efficiency and cost‑effectiveness.

Application Scenarios

1. HIV Protease Inhibitor Development for Antiretroviral Therapy

A pharmaceutical research team is developing new non‑peptide HIV protease inhibitors for the treatment of HIV/AIDS, with the goal of overcoming drug resistance and improving patient compliance. (S)-3-Aminobutanenitrile hydrochloride serves as a chiral intermediate in the synthesis of these inhibitors. The (S)-configuration at the chiral center is critical for achieving high binding affinity to the HIV protease active site, as the target enzyme exhibits strict chiral discrimination. Using (S)-3-aminobutanenitrile hydrochloride ensures the final API possesses the correct three‑dimensional geometry for optimal target engagement. The team synthesizes a focused library of derivatives via functionalization of the amino group, and the resulting compounds are screened for HIV protease inhibitory activity using fluorometric or chromatographic assays to identify leads with improved potency and pharmacokinetic profiles.

2.GLP‑1 Agonist Synthesis for Type‑II Diabetes (Orforglipron)

A pharmaceutical manufacturer is scaling up the synthesis of Orforglipron, a GLP‑1 agonist used for the treatment of Type‑II diabetes. (S)-3-Aminobutanenitrile hydrochloride serves as a documented chiral intermediate, with the (S)-enantiomer being a key active structural unit of the drug molecule. The team utilizes the compound in a multi‑step synthesis sequence: first, the amino group is protected, then the nitrile is reduced to the corresponding amine, and finally, the protected intermediate is coupled with other building blocks to construct the complete drug scaffold. The high optical purity (≥99% ee) of (S)-3-aminobutanenitrile hydrochloride is essential for achieving the correct stereochemistry of the final API, which directly impacts its binding affinity to the GLP‑1 receptor, therapeutic efficacy, and safety profile.

3. Chiral Drug Synthesis for Tuberculosis and Viral Infections

A medicinal chemistry team is exploring new chemical entities for the treatment of drug‑resistant tuberculosis and viral infections. The (S)-configured chiral amino structure is known to be a key active unit of drug molecules for these therapeutic areas. The team uses (S)-3-aminobutanenitrile hydrochloride as a core chiral building block to synthesize a library of derivatives via amide coupling, reductive amination, and nitrile reduction. The resulting compounds are screened for anti‑tubercular activity against M. tuberculosis H37Rv and for anti‑viral activity against relevant viral strains. Through precise chiral construction, the team ensures that the synthesized drug candidates exhibit specific binding to their targets, improving efficacy and reducing off‑target side effects.

4. Chiral Pesticide Development (Fungicides and Insecticides)

An agrochemical research center is developing high‑efficiency, low‑toxicity chiral pesticides to meet the growing demand for environmentally friendly crop protection agents. (S)-3-Aminobutanenitrile hydrochloride is used as a chiral building block for the synthesis of novel fungicides and insecticides. The reactivity of its amino and cyano groups allows it to participate in heterocycle construction and functional group modification reactions, optimizing the biological activity, targeting, and environmental compatibility of the final pesticide products. The team synthesizes a series of chiral pesticide candidates and evaluates their efficacy against plant‑pathogenic fungi and agricultural pests in greenhouse trials, identifying lead compounds with superior activity and lower environmental impact.

5. Chiral Ligand Synthesis for Asymmetric Catalysis

A research group in asymmetric catalysis requires a library of chiral ligands for enantioselective transformations, such as hydrogenation, cross‑coupling, and C‑H functionalization. (S)-3-Aminobutanenitrile hydrochloride serves as a versatile chiral building block for the synthesis of various fine chemicals, including chiral ligands and optically active materials. The team converts the compound into phosphine ligands, oxazoline ligands, or Schiff base ligands via functionalization of the amino group and further derivatization of the nitrile. The resulting chiral ligands are evaluated for their performance in asymmetric catalysis, with the aim of developing cost‑effective and high‑performance catalysts for industrial applications.

6. Chiral Intermediate Library Synthesis for CNS Drug Discovery

A drug discovery group focusing on central nervous system (CNS) disorders requires a diverse library of chiral intermediates to explore novel chemical space. (S)-3-Aminobutanenitrile hydrochloride is utilized as a core building block for constructing β-amino alcohol derivatives (via nitrile reduction) and other chiral motifs. The team performs parallel synthesis to generate a focused library of compounds, which are then screened for CNS activity in cell‑based assays (e.g., neuroprotection, receptor binding). The high stability and solubility of the hydrochloride salt form facilitate reliable handling and reproducible reactions across the library synthesis.

Quality Assurance at Cosperpharm

Each batch undergoes:

● Gas chromatography (GC) – purity ≥97.0%

● Non‑aqueous titration – purity ≥97.0%

● Refractive index – confirmatory analysis

● ¹H NMR – structural verification

● Appearance – colorless to light yellow to light orange clear liquid

A comprehensive COA, MSDS (with full GHS information), and certificate of origin accompany every shipment.

Contact Us

We look forward to supporting your research and development needs.If you have any questions regarding (S)-3-Aminobutanenitrile hydrochloride (CAS 1073666-54-2) or wish to request a quotation, please do not hesitate to reach out. Our sales and technical support teams are ready to assist you.